The United Kingdom’s vaccination programme has been a beacon for the world in many ways and It is a matter of great satisfaction that an India-UK collaboration in vaccine manufacture here in the UK has played a vital part in the roll out, said High Commissioner of India, Gaitri Issar Kumar on her visit to Wockhardt UK facility. 

The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector, added Kumar.

Dr. Habil Khorakiwala, Founder Chairman, Wockhardt said, “The COVID-19 pandemic has been a challenge for all and it needed a concerted effort to overcome. We are proud to be an Indian-led company working in collaboration with the UK government with our innovative international operations in Wales. It is an honour to be recognised for our capability and commitment by the visit from the Indian High Commissioner to the UK, Gaitri Issar Kumar.”

Dr Murtaza Khorakiwala, Managing Director and Global CEO of Wockhardt commented, “We were honoured to have a visit from the High Commissioner of India to recognise our India-UK collaboration and essential role in mitigating the global impact of COVID-19.”

Ravi Limaye, Managing Director of Wockhardt UK commented, “It was an honour to share our pride in the delivery of the vaccine programme to the High Commissioner, Gaitri Issar Kumar and to demonstrate the impact that Indian-led pharmaceutical innovation is having in the global fight against the COVID-19 pandemic.”

As part of her visit, The High Commissioner was provided with a tour of the state-of-the-art vaccine fill finish facility which is currently contracted by the UK Government to manufacture the Oxford/AstraZeneca COVID-19 vaccine until August 2022. The High Commissioner was joined by the Indian Honorary Consul for Wales, Raj Aggarwal OBE, RNR.